|
|
Article: Genomic signature of colon cancer may individualize treatment.
- Article from:
- Biotech Week
- Article date:
- December 10, 2008
CopyrightCOPYRIGHT 2008 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Researchers in the Duke Institute for Genome Sciences & Policy have developed a model for predicting risk of recurrence in early stage colon cancer patients, and have used the model to also predict sensitivity to chemotherapy and targeted therapy regimens (see also Duke University Medical Center).
"These findings have important implications for individualizing therapy," said Katherine Garman, M.D., a gastroenterology fellow at Duke and lead investigator on the study. "By examining gene expression in early-stage colon cancer tumors, we have found certain patterns that seem to put some patients at higher risk for recurrence. By identifying these patients up front, ...